奥沙利铂联合卡培他滨一线治疗晚期转移性胃癌的临床疗效观察

目的探讨奥沙利铂联合卡培他滨作为一线方案治疗晚期转移性胃癌的疗效和安全性。方法27例既往未接受过化疗的晚期转移性胃癌患者采用奥沙利铂联合卡培他滨（XELOX方案）化疗：奥沙利铂130 mg/m²，静脉滴注2小时,d1；卡培他滨2 000 mg/m²，分2次口服,d1～14，21天为一周期。患者最多接受8个周期化疗。结果27例患者共接受124个周期化疗，中位化疗周期数为5个。所有患者均可评价疗效，其中部分缓解12例(44.5%)，稳定8例(29.6%), 进展7例(25.9%)；客观有效率44.5%(95%可信区间:25.8%～63.2%)。平均随访9.2月，中位疾病进展时间5.0月（95%可信区间：2.6～7.4月），中位生存时间9.7月（95%可信区间：6.5～12.9月）。常见不良反应有骨髓抑制、外周神经毒性、胃肠道反应、手足综合征等，无治疗相关性死亡。结论XELOX方案一线治疗晚期转移性胃癌疗效显著,耐受性良好。

Oxaliplatin in Combination with Capecitabine as First-line Chemotherapy for Patients with Metastatic Gastric Cancer

Objective To investigate the efficacy and safety of oxaliplatin in combination with capecitabine as first-line chemotherapy for patients with metastatic gastric cancer. Methods Twenty-seven chemother-apy-na ve patients with metastatic gastric cancer participated in the study. They received oxaliplatin 130 mg/m~2 as 2-hour intravenous infusion on day 1 and oral capecitabine 2 000 mg/m~2 divided into two daily doses on days 1～14 every 21 days (XELOX regimen). Maximum 8 cycles were given. Results Twenty-seven patients completed 124 cycles of chemotherapy with a median number of five cycles. All patients could be evaluated for efficacy. The response rate was 44.5% (95% confidence interval: 25.8%～ 63.2%), with 12 partial responses (44.5%), 8 stable diseases (29.6%), and 7 progression diseases (25.9%). At 9.2 months mean follow-up, median time to progression and overall survival were 5.0 (95% confidence interval: 2. 6~7. 4) and 9. 7 months (95% confidence interval: 6. 5～12. 9) respectively. Common adverse events included bone marrow suppression, peripheral neuropathy, diarrhea, nausea/ vomiting and hand-foot syndrome. There was no treatment-related death. Conclusion XELOX regimen is active and well-tolerated as first-line chemotherapy for patients with metastatic gastric cancer.